Divi’s Labs

Expensive valuations may limit upside for Divi's Laboratories stock

Despite strong custom synthesis growth and better-than-expected quarterly results, analysts caution that high valuations could restrict near-term gains for Divi's Laboratories

Divis Labs rallies 13% in 1 week; What's driving pharma stock?

Divis stock gained 2% in Monday's intra-day deals. Reports suggest the company is well positioned to benefit from emerging trends across both API and CDMO domains through innovation and capex.

Divi's Labs falls 4% after Q1 miss, analysts trim estimates; check details

Divi's Laboratories reported a 14 per cent year-on-year jump in revenue at ₹2,410 crore in Q1FY26, compared to ₹2,118 crore in the year-ago period

Analyst suggest Nifty investment strategy; GAIL, Tata Steel among top bets

The recent price action in the Nifty indicates that the bulls are making a strong effort to sustain the prevailing uptrend. Buy GAIL, Tata Steel and this one stock today

Divi's Lab Q3 result: Profit up 65% to Rs 589 cr on robust market sales

Drug firm Divi's Laboratories on Monday said its profit after tax (PAT) increased 65 per cent to Rs 589 crore for the December quarter, on the back of robust sales across markets. The company had reported a profit after tax (PAT) of Rs 358 crore for the October-December quarter of last fiscal. Revenue from operations rose to Rs 2,319 crore in the third quarter as against Rs 1,855 crore in the year-ago period, Divi's Laboratories said in a regulatory filing. The drug firm noted a part of the Kakinada Project (Unit-III) commenced commercial operations from January 1, 2025. The rest of Kakinada project is being implemented and is expected to be operational in about six months, it added. "We have capitalised assets of Rs 433 crore for the quarter and of Rs 557 crore for the nine-month period of the current fiscal year. Of this, capitalisation for Kakinada Project is Rs 418 crore during the 9-month period," the drug firm stated. The company said its board has approved the re-appointme

Divi's Labs Q3 results: PAT rises 64.5% to Rs 589 cr on strong API demand

Its revenue from operations climbed 25 per cent to Rs 2,319 crore during the quarter, roughly in line with analysts' estimate of Rs 2,343 crore

Valuations may offset Q4 show, growth outlook for Divi's Laboratories

The company delivered a strong revenue and operating performance in the March quarter

Lowering prices to weigh down earnings of Indian API players in near term

According to the brokerage, prices of APIs such as Paracetamol, Azithromycin, Montelukast, and Meropenem, have all declined in the range of 10-30 per cent over the last one year

Pidilite, Nestle: Select stks in Rahul Gandhi's portfolio can dip up to 12%

As per an affidavit filed with the Election Commission of India, Rahul Gandhi's top stock holdings include Pidilite Industries, Bajaj Finance, Nestle, ITC, Hindustan Unilever and Tube Investments.

Growth and margin uptick critical for gains in Divi's Laboratories

Motilal Oswal Research is factoring in 25 per cent net profit growth annually over the FY23-25 period adjusting for Covid-led business in FY23

Divi's Laboratories Q2FY24 result: Net profit dips 29% to Rs 348 crore

Divi's Labs Q2 result: The revenue from operations, however, rose 3 per cent to Rs 1,909 crore in the period from Rs 1,855 crore last year

Divi's stock may underperform on valuations, near term growth concerns

Revenue of the contract research and manufacturing services player was down 21 per cent y-o-y

Divi's Labs stock tanks 12% on big miss in Q3; near-term trend 'bearish'

Analysts' average price target of Rs 3,862, however, indicates significant upside. The near-term trend remains bearish

Brokerages downgrade Divi's Labs post Q2 letdown; stock falls 11% in 2 days

EBITDA margins declined 767 bps YoY to 33.5 per cent due to high energy and transport costs.

Growth worries to keep Divi's Labs under pressure in the near term

Valuations, too, are on the higher side, say brokerages

Six Indian drug firms that are doing serious business in coronavirus times

The world's race for a coronavirus drug hinges on Indian companies working with their global peers. Business Standard tracks six companies to feel the pulse of Indian pharma

Divi's Labs: New capex, margin expansion to support earnings growth

Brokerages expect the company's net profits to grow by 30 per cent annually over FY20-23

Infosys, PI Industries, ICICI Bank: Top picks of brokerages for Samvat 2077

According to Axis Securities, the small and midcaps are picking up steam and they should deliver solid returns in 2021 as economic uncertainties will reduce and volatility will decline

Divi's Laboratories begins commercial production at Visakhapatnam unit

Divi's Laboratories, established in Hyderabad, is a pharmaceutical company with two manufacturing units

Choke in API supplies from China creates huge opportunity for Divi's Labs

Niche capabilities and absence of regulatory overhangs are other key positives